Saturday 17 October 2026 Export IMCR’s income statement to Excel — free account

Immunocore Holdings PLC Sponsored ADR

Immunocore Holdings PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $400.0 million, up 29.0% from fiscal 2024. In the quarter to June 2026, revenue grew 18.3%, EPS grew 92.1%, free cash flow fell 40.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years.

29.40 0.08 −0.27%

Follow IMCR

Alert me

Market cap: $1.5B
P/E: 0.0×
Fwd P/E: 208×
Dividend yield: —
F-score: 3/9
Altman Z: 1.52
Beneish M: −2.40
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 5.63

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	1	—	4	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 1,520.00

Revenue 430.78

Net Income (18.07)

Free Cash Flow (41.15)

Net Debt (486.00)

Current Ratio 4.47

Debt/Equity 0.94

P/E ratio 0.00

Fwd P/E 208.00

P/S ratio 3.48

P/B ratio 3.57

Past 5Y EPS Growth —

This Y EPS Growth 92.03%

Next Y EPS Growth (941.12%)

Next Y revenue growth 48.78%

Next 5Y EPS Growth 71.86%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.05%

10-year low 10-year high

P/B against its own 10 years 0.93%

10-year low 10-year high

EV/Sales against its own 10 years 0.75%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	443	820	864	880
Receivables	52	63	76	95
Inventory	5	5	7	8
Other	—	—	—	—
	529	930	997	1,051

	2023	2024	2025	Q'26
Payables	18	25	24	26
ST’ Debt	—	—	—	—
Other	—	—	—	—
	139	212	247	235

Compound Annual Growth %

	10y	5y	3y
Sales	—	59.57%	31.89%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	39.91%	3.98%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	107	116	—	—	—
’25	94	98	104	104	400
’24	71	75	80	84	310
’23	55	60	65	70	249
’22	30	40	49	56	174
’21	11	8	8	9	36
’20	—	—	—	10	39

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(14)	16	—	—	—
’25	0	26	(4)	(33)	(11)
’24	(5)	23	21	(14)	26
’23	11	0	10	(18)	3
’22	(41)	(9)	13	(12)	(49)
’21	(36)	(46)	(28)	(22)	(132)
’20	—	—	(52)	(26)	(78)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	15	—	—	—
’25	0	26	(5)	(36)	(15)
’24	(5)	23	20	(17)	21
’23	8	(1)	10	(19)	(2)
’22	(42)	(9)	12	(13)	(52)
’21	(36)	(46)	(29)	(23)	(133)
’20	—	—	(55)	(26)	(81)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.25	(0.02)	—	—	—
’25	0.10	(0.20)	0.00	(0.60)	(0.71)
’24	(0.49)	(0.23)	0.17	(0.47)	(1.02)
’23	(0.43)	(0.37)	0.02	(0.40)	(1.13)
’22	(0.48)	(0.17)	0.14	(0.63)	(1.09)
’21	(1.05)	(1.04)	(0.95)	(1.21)	(4.19)
’20	—	—	—	(0.78)	(3.58)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	26.03	18.43	42.21	27.69	23.15	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	61.99	69.06	70.98	76.98	40.72
People
People	Employees	—	—	—	291	291	324	408	497	493	524
	Revenue/emp, $m	—	—	0.00	0.11	0.13	0.11	0.43	0.50	0.63	0.76
Income, $m
Income, $m	Revenue	—	—	32	33	39	36	174	249	310	400
	Gross margin, %	—	—	0.00	100.00	100.00	100.00	99.38	99.58	99.12	98.73
	EBT	—	—	(118)	(161)	(112)	(194)	(41)	(61)	(53)	(19)
	EBT margin, %	—	—	(373.79)	(491.60)	(290.10)	(531.40)	(23.45)	(24.41)	(17.07)	(4.77)
	Net income	—	0	(96)	(133)	(95)	(181)	(53)	(55)	(51)	(36)
	Depreciation	—	—	9	12	12	10	5	4	4	3
Per share, $
Per share, $	Revenue	—	—	0.00	7.35	1.46	0.86	3.81	5.10	6.21	7.95
	Earnings	—	—	(2.26)	(29.76)	(3.58)	(4.19)	(1.09)	(1.13)	(1.02)	(0.71)
	Cash flow	—	—	0.00	(29.03)	(2.93)	(3.11)	(1.08)	0.06	0.52	(0.21)
	Capex	—	—	0.00	(1.20)	(0.12)	(0.03)	(0.06)	(0.11)	(0.10)	(0.09)
	Free cash flow	—	—	0.00	(30.23)	(3.05)	(3.14)	(1.14)	(0.05)	0.42	(0.30)
	Book value	—	—	0.00	4.23	2.68	5.55	7.41	7.54	7.22	7.57
	Shares, m	—	—	—	4	27	42	46	49	50	50
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	0.00	0.00	0.00	39.89	14.53	14.04	4.75	4.37
	P/B	—	—	0.00	0.00	0.00	6.17	7.48	9.50	4.09	4.59
	EV/Sales	—	—	0.00	0.00	0.00	33.33	12.51	12.46	3.53	3.31
	EV/FCF	—	—	0.00	0.00	0.00	(9.11)	(42.42)	(1,251.14)	52.24	(88.01)
Cash, $m
Cash, $m	Operating cash flow	—	—	(22)	(129)	(78)	(132)	(49)	3	26	(11)
	Capex	—	—	(5)	(5)	(3)	(1)	(3)	(5)	(5)	(4)
	Free cash flow	—	—	(22)	(135)	(81)	(133)	(52)	(2)	21	(15)
Balance, $m
Balance, $m	Working capital	—	—	155	51	126	277	373	390	718	750
	Total debt	—	—	24	73	79	86	48	48	391	393
	Net debt	—	—	(134)	(21)	(87)	(241)	(355)	(395)	(429)	(471)
	Shareholders’ equity	—	—	72	19	71	236	339	369	361	381
Returns, %
Returns, %	ROA	—	—	(76.61)	(54.57)	(38.81)	(54.14)	(11.16)	(9.84)	(6.36)	(3.42)
	ROIC	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	—	(208.47)	(291.91)	(211.59)	(117.84)	(18.28)	(15.62)	(14.00)	(9.58)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NTLA Intellia Therapeutics, Inc.	$1.6B	— (loss-making)	— (loss-making)	−46.23% (below 0%: shrinking)	n/m	+15.05% (above 0%: growing)	100.00%	(1,472.25%)	Compare
GPCR Structure Therapeutics Inc. Sponsored ADR	$1.6B	— (loss-making)	—	—	n/m	−119.15% (below 0%: shrinking)	0.00%	0.00%	Compare
QURE uniQure N.V.	$1.6B	— (loss-making)	— (loss-making)	+11.00% (above 0%: growing)	n/m	+27.66% (above 0%: growing)	94.01%	(893.73%)	Compare
KRSA Korsana Biosciences, Inc.	$1.5B	— (loss-making)	— (loss-making)	−43.24% (below 0%: shrinking)	n/m	−184.69% (below 0%: shrinking)	100.00%	0.00%	Compare
MAZE Maze Therapeutics, Inc.	$1.5B	— (loss-making)	—	—	n/m	+50.21% (above 0%: growing)	100.00%	0.00%	Compare
IMCR Immunocore Holdings PLC Sponsored ADR	$1.5B	— (loss-making)	208×	+18.34% (above 0%: growing)	n/m	−40.74% (below 0%: shrinking)	99.06%	(2.58%)
ABSI Absci Corporation	$1.5B	— (loss-making)	— (loss-making)	−46.37% (below 0%: shrinking)	n/m	−71.74% (below 0%: shrinking)	100.00%	(10,741.51%)	Compare
RARE Ultragenyx Pharmaceutical Inc.	$1.5B	— (loss-making)	— (loss-making)	+28.14% (above 0%: growing)	n/m	+12.50% (above 0%: growing)	84.11%	(35.05%)	Compare
ANAB AnaptysBio, Inc.	$1.5B	— (loss-making)	220×	−7.98% (below 0%: shrinking)	n/m	−141.60% (below 0%: shrinking)	100.00%	(135.53%)	Compare
Median of peers	$1.5B	—	—	−25.61%	—	−29.62%	100.00%	(85.29%)

All 614 Biotechnology stocks →